This is BrainsWay’s global website. The website includes information on clinical indications that were not cleared by the FDA and are considered investigational by the U.S. medical device regulations. The FDA cleared BrainsWay D treatment of Major Depression in patients who failed to respond to one or more anti-depressants in the current episode.
Bloch, Y., Arad, S., & Levkovitz, Y. (2014). World Journal of Biological Psychiatry, (Epub ahead of print).
This study explores the effect of Brainsway® Deep TMS (Transcranial Magnetic Stimulation) on adults who suffer from intractable Tourette Syndrome (TS). The study enrolled 12 patients and was held over 20 days. The study found no significant side effects, and indicated that Deep TMS is safe for treating TS. In the study, the subgroup who suffered from both TS and Obsessive Compulsive Disorder (OCD) experienced significant improvement – a beneficial result that also indicates that TS is not of a uniform nature.